Skip to main content
Premium Trial:

Request an Annual Quote

Phase-1 Becomes Authorized Affymetrix Service Provider

NEW YORK, May 16 - Phase-1 Molecular Toxicology has become an authorized service provider for scanning and analysis of Affymetrix GeneChip brand microarrays, the company said yesterday.


The Santa Fe, N.M.-based company said it can now provide services for both cDNA and Affymetrix-type microarrays.


Phase-1, which focuses on toxicogenomics, offers products and services for animal and human gene expression.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.